Vol 46: A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.Report as inadecuate



 Vol 46: A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.


Vol 46: A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer. - Download this document for free, or read online. Document in PDF available to download.

Download or read this book online for free in PDF: Vol 46: A Phase I Study of Oral Paclitaxel with a Novel P-Glycoprotein Inhibitor, HM30181A, in Patients with Advanced Solid Cancer.
This article is from Cancer Research and Treatment : Official Journal of Korean Cancer Association, volume 46.AbstractPurpose: The purpose of this study is to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, and recommended phase II dose of an oral drug composed of paclitaxel and HM30181A, which is an inhibitor of P-glycoprotei

Author: Lee, Hyun Jung; Heo, Dae-Seog; Cho, Joo-Youn; Han, Sae-Won; Chang, Hye-Jung; Yi, Hyeon-Gyu; Kim, Tae-Eun; Lee, Se-Hoon; Oh, Do-Youn; Im, Seock-Ah; Jan

Source: https://archive.org/







Related documents